San Diego, CA, United States of America

Yifeng Xia

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Hangzhou Glubio Pharmaceutical Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yifeng Xia: Innovator in Pharmaceutical Compounds

Introduction

Yifeng Xia is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on isoindolinone compounds.

Latest Patents

Yifeng Xia holds a patent for isoindolinone compounds and their uses. The patent describes isoindolinone compounds represented by a specific structural formula or pharmaceutically acceptable salts thereof. These compounds can be utilized for the treatment of proliferative disorders. The pharmaceutical compositions include the isoindolinone compound or a salt thereof, along with a pharmaceutically acceptable carrier.

Career Highlights

Yifeng Xia is associated with Hangzhou Glubio Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has led to the creation of valuable pharmaceutical products that have the potential to improve patient outcomes.

Collaborations

Yifeng Xia has collaborated with notable colleagues, including Liqiang Fu and Linglong Kong. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.

Conclusion

Yifeng Xia's contributions to the field of pharmaceuticals through his patent on isoindolinone compounds exemplify his commitment to advancing medical science. His work continues to impact the treatment of proliferative disorders, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…